7 research outputs found

    Characteristics of the study women (N = 635).

    No full text
    <p>IQR, interquartile range; HAART, highly active antiretroviral therapy.</p>a<p>HCV status was determined at enrollment. Follow-up HCV RNA testing was conducted on all women who were HCVAb+ at enrollment and HCV RNA status was 100% concordant between enrollment and follow-up testing (see Laboratory Methods).</p>b<p>Four women had missing CD4+ data at their CMV testing visit.</p>c<p>Untreated: no receipt of HAART; Treated and aviremic: undetectable HIV RNA for ≥50% of study visits following first reported receipt of HAART; Treated and viremic: HIV RNA levels above the lower level of detection for >50% of study visits following first reported receipt of HAART.</p

    Median CMV IgG levels (IU/mL) stratified by HCV RNA status, age tertile, and HIV treatment status among CMV-seropositive women.

    No full text
    a<p>Women who were HCVAb+/HCV RNA+ at enrollment were defined to be HCV RNA+ while those who were HCV Ab+/HCV RNA- and HCVAb- at enrollment were defined to be HCV RNA-. Follow-up HCV RNA testing was conducted on all women who were HCVAb+ at enrollment and HCV RNA status was 100% concordant between enrollment and follow-up testing. Follow-up testing of HCVAb- women was not conducted (see Laboratory Methods and Discussion).</p>b<p><i>P</i> values calculated using Mann-Whitney tests.</p>c<p>Age tertiles. Low: <37.6; Middle: 37.6–45.3; High: >45.3. The low and middle age tertiles were combined because of the small number of HCV RNA positive women in the low age tertile.</p

    Independent associations of HCV RNA status and covariates with CMV IgG (IU/mL)<sup>a</sup>.

    No full text
    a<p>Results from a single multivariable linear regression model of N = 584 women who were both CMV and EBV seropositive and had CD4+ T-cell data at their CMV testing visit.</p>b<p>Women who were HCVAb+/HCV RNA+ at enrollment were defined to be HCV RNA+ while those who were HCV Ab+/HCV RNA- and HCVAb- at enrollment were defined to be HCV RNA-. Follow-up HCV RNA testing was conducted on all women who were HCVAb+ at enrollment and HCV RNA status was 100% concordant between enrollment and follow-up testing. Follow-up testing of HCVAb- women was not conducted (see Laboratory Methods and Discussion).</p>c<p>Age tertiles. Low: <37.6; Middle: 37.6–45.3; High: >45.3.</p>d<p>Untreated: no receipt of HAART; Treated and aviremic: undetectable HIV RNA for ≥50% of study visits following first reported receipt of HAART; Treated and viremic: HIV RNA levels above the lower level of detection for >50% of study visits following first reported receipt of HAART.</p
    corecore